Vernalis inks financing deal

Vernalis has signed a €18.4M financing agreement with Paul Capital Healthcare for frovatriptan, Vernalis' migraine drug. In return for the cash, Paul Capital Healthcare will receive approximately 90 percent of Menarini's payments to Vernalis under their agreement for the commercialization of frovatriptan. According to Hemscott, "the plan was a way for it to meet its debt obligations to U.S. Frova marketing partner Endo Pharmaceutical, which had been valued at $56 million and represented a 'sword of Damocles' for Vernalis." In a release, Vernalis' CFO Tony Weir said the financing deal will allow the company to rebuild new shareholder value in the medium term.

- here's the release
- read the Hemscott report

Suggested Articles

AstraZeneca is picking up a delayed preclinical fibrosis candidate from RedX in a deal that gives the U.K. biotech a much needed cash boost.

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.